Afoxolaner Merial is a veterinary medicine used to treat infestations with fleas and ticks, as well as demodectic and sarcoptic mange (skin infestations caused by two different types of mites) in dogs. It may be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).
Afoxolaner Merial contains the active substance afoxolaner. This medicine is the same as NexGard, which is already authorised in the European Union (EU). The company that makes NexGard has agreed that its scientific data can be used for Afoxolaner Merial (‘informed consent’).
Afoxolaner Merial : EPAR - Medicine overview (PDF/76.44 KB)
First published: 07/06/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Boehringer Ingelheim Vetmedica GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
16/12/2019 Afoxolaner Merial - EMEA/V/C/005126 - T/0002
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Treatment of flea (Ctenocephalides felis and C. canis) infestations. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Treatment of tick (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) infestations.
Treatment of demodicosis (caused by Demodex canis).
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).